TaiRx, Inc. (TPEX:6580)
Taiwan · Delayed Price · Currency is TWD 23.10
-0.30 (-1.28%)
Aug 12, 2025, 12:05 PM CST
Paramount Global Revenue
In the year 2024, TaiRx had annual revenue of 8.22M TWD with 61.79% growth. TaiRx had revenue of 7.96M in the half year ending December 31, 2024, with 26.20% growth.
Revenue
8.22M
Revenue Growth
+61.79%
P/S Ratio
315.03
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.22M | 3.14M | 61.79% |
| Dec 31, 2023 | 5.08M | -1.84M | -26.59% |
| Dec 31, 2022 | 6.92M | 1.78M | 34.66% |
| Dec 31, 2021 | 5.14M | 1.78M | 53.05% |
| Dec 31, 2020 | 3.36M | 203.00K | 6.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 40.47M |
| PharmaEssentia | 11.34B |
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| Oneness Biotech | 112.57M |
| Polaris Group | 87.67M |
| Center Laboratories | 1.63B |
| Pegavision | 6.67B |